SCHEMBL740292

SCHEMBL740292

CC(C)(NC(=O)c1cc2c(NC(=O)c3ccccc3)n[nH]c2s1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 1/20 0.55
▸ ABL1 P00519 2/20 0.53
▸ BCR P11274 2/20 0.53
▸ FGFR1 P11362 3/20 0.43
▸ FGFR2 P21802 2/20 0.43
▸ FGFR3 P22607 2/20 0.43
▸ CDK7 P50613 5/20 0.42
▸ MEN1 O00255 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ IMPDH2 P12268 1/20 0.40
▸ CCNA2 P20248 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ CCNA1 P78396 1/20 0.39
▸ KCNK9 Q9NPC2 1/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL740809 0.94 AURKA (0.52) AURKAABL1BCRFGFR1FGFR2
SCHEMBL1779700 0.93 AURKA (0.50) AURKAABL1BCRNPC1ALDH1A1
SCHEMBL741311 0.93 AURKA (0.53) AURKAABL1BCRFGFR1CDK7
SCHEMBL738866 0.93 AURKA (0.53) AURKAABL1BCRFGFR1FGFR2
SCHEMBL740955 0.91 CDK7 (0.48) AURKAABL1BCRCDK7MEN1
SCHEMBL741609 0.91 AURKA (0.52) AURKAABL1BCRCDK7MEN1
SCHEMBL739779 0.91 AURKA (0.52) AURKAABL1BCRFGFR1FGFR2
SCHEMBL741926 0.91 AURKA (0.52) AURKAABL1BCRFGFR1FGFR2
SCHEMBL742124 0.91 AURKA (0.48) AURKAABL1BCRFGFR1FGFR3
SCHEMBL743719 0.91 ABL1 (0.55) AURKAABL1BCRFGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 — — US claimed
EP-2007380-B1 USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS NERVIANO MEDICAL SCIENCES SRL (IT) 2011-09-14 — — EP claimed
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 — — US disclosed
EP-2007380-B1 USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS NERVIANO MEDICAL SCIENCES SRL (IT) 2011-09-14 — — EP disclosed
Send feedback